Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 - 2025

Researchmoz added Most up-to-date research on "Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016 - 2025" to its huge collection of research reports.

Non-alcoholic steatohepatitis or NASH is a common term for “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). NASH is also associated with lysosomal acid lipase deficiency. Patients with only steatosis but no fibrosis can progress to NASH.

NASH itself can remain asymptomatic for years, or it can progress to cirrhosis and hepatocellular carcinoma. Risk factors such as insulin resistance related to obesity are central to the pathogenesis of NASH. Methods to diagnose NASH include MRI, CT or X-rays, however, only liver biopsy is reliable. There are no approved NASH drugs available in the market, but they are expected to enter the market by 2020. The potential NASH drug candidate include Elafirbranor, OCA, CVC and Aramchol. Currently, off-label drugs and therapies are employed to counter the progression of NASH.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=883532

The global NASH drugs market is expected to experience robust growth post the launch of NASH therapeutic drugs, primarily due to increasing patient base, rise in obese population, increasing number of people suffering from type-2 diabetes coupled with increasing healthcare expenditure. However, the market growth is hindered by the unavailability of effective biomarkers, high cost of drugs and undefined pathogenesis.

The report “Global NASH Drugs Market: Industry Analysis & Outlook (2016-2020)” analyzes the development of this market, with focus on the US and Europe markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.

Browse More Details @ http://www.researchmoz.us/global-nonalcoholic-steatohepatitis-nash-drugs-market-industry-analysis-outlook-20162025-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.